EPIGENESIS PHARMACEUTICALS EE

Serial Number 77585606
606

Registration Progress

Application Filed
Oct 3, 2008
Under Examination
May 19, 2009
Approved for Publication
Feb 4, 2009
Published for Opposition
Feb 24, 2009
Registered

Trademark Image

EPIGENESIS PHARMACEUTICALS EE

Basic Information

Serial Number
77585606
Filing Date
October 3, 2008
Published for Opposition
February 24, 2009
Abandonment Date
June 20, 2011
Drawing Code
5000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jun 20, 2011
Classes
005

Rights Holder

Epigenesis Pharmaceuticals, LLC

16
Address
2009 Eastpark Boulevard
Cranbury, NJ 08512

Ownership History

Epigenesis Pharmaceuticals, LLC

Original Applicant
16
Cranbury, NJ

Epigenesis Pharmaceuticals, LLC

Owner at Publication
16
Cranbury, NJ

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

29 events
Date Code Type Description Documents
Jun 20, 2011 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Jun 20, 2011 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
May 5, 2011 WOAR I TEAS WITHDRAWAL OF ATTORNEY RECEIVED Loading...
May 5, 2011 WOAG I WITHDRAWAL OF ATTORNEY GRANTED Loading...
Nov 6, 2010 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 5, 2010 EX3G S SOU EXTENSION 3 GRANTED Loading...
Nov 4, 2010 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 4, 2010 EXT3 S SOU EXTENSION 3 FILED Loading...
Jun 4, 2010 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 3, 2010 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jun 3, 2010 EX2G S SOU EXTENSION 2 GRANTED Loading...
May 17, 2010 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 17, 2010 EXT2 S SOU EXTENSION 2 FILED Loading...
Nov 3, 2009 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 3, 2009 EXT1 S SOU EXTENSION 1 FILED Loading...
Nov 3, 2009 EX1G S SOU EXTENSION 1 GRANTED Loading...
May 19, 2009 NOAM O NOA MAILED - SOU REQUIRED FROM APPLICANT Loading...
Feb 24, 2009 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 4, 2009 NPUB O NOTICE OF PUBLICATION Loading...
Jan 22, 2009 ALIE A ASSIGNED TO LIE Loading...
Jan 22, 2009 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Jan 6, 2009 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jan 6, 2009 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Jan 6, 2009 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jan 6, 2009 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jan 6, 2009 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 30, 2008 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 8, 2008 MPMK O NOTICE OF PSEUDO MARK MAILED Loading...
Oct 7, 2008 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
medical diagnostic and therapeutic preparations, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold filled, the preparations including nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ARDS), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (SVT), adenosine stress tests, infantile respiratory distress syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostate
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Design Mark
The mark consists of the words "EPIGENESIS PHARMACEUTICALS" and two stylized versions of the letter "E", one facing right and one facing left.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMACEUTICALS"